Free Trial
NASDAQ:NAGE

Niagen Bioscience 8/6/2025 Earnings Report

Niagen Bioscience logo
$9.90 +0.08 (+0.81%)
As of 08/29/2025 04:00 PM Eastern

Niagen Bioscience EPS Results

Actual EPS
$0.04
Consensus EPS
$0.02
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Niagen Bioscience Revenue Results

Actual Revenue
$31.12 million
Expected Revenue
$28.55 million
Beat/Miss
Beat by +$2.57 million
YoY Revenue Growth
N/A

Niagen Bioscience Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Niagen Bioscience Earnings Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Unlocking Cellular Health With Science and Trust
See More Niagen Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email.

About Niagen Bioscience

Niagen Bioscience (NASDAQ:NAGE) is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

View Niagen Bioscience Profile

More Earnings Resources from MarketBeat